AstraZeneca Prices Iressa At 25% Discount To Gleevec; Launch In May
AstraZeneca is launching the lung cancer agent Iressa at a 25% discount to Novartis' chronic myelogenous leukemia therapy Gleevec
AstraZeneca is launching the lung cancer agent Iressa at a 25% discount to Novartis' chronic myelogenous leukemia therapy Gleevec